Sin­ga­pore­an cell ther­a­py biotech with off-the-shelf am­bi­tions wraps mod­est IPO

Al­most five months af­ter first fil­ing for an IPO, a small Sin­ga­pore­an cell ther­a­py biotech is land­ing on the Nas­daq.

Cy­toMed Ther­a­peu­tics man­aged to raise slight­ly more than $9.6 mil­lion by pric­ing its stock at $4 per share. It’s not a large sum, es­pe­cial­ly for a com­pa­ny whose am­bi­tion is to de­vel­op off-the-shelf cell ther­a­pies for can­cer, but it does sub­stan­tial­ly boost Cy­toMed’s re­serves — which it count­ed at around $1.07 mil­lion as of last June.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.